Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.57 |
| ▸ | CNR2 | P34972 | 12/20 | 0.56 |
| ▸ | CNR1 | P21554 | 10/20 | 0.50 |
| ▸ | BCHE | P06276 | 8/20 | 0.50 |
| ▸ | ACHE | P22303 | 2/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6580236 | 0.89 | LMNA (0.56) | L3MBTL1CNR2CNR1BCHEACHE | |
| SCHEMBL6586815 | 0.86 | L3MBTL1 (0.73) | L3MBTL1CNR2CNR1BCHEATM | |
| SCHEMBL6583139 | 0.78 | L3MBTL1 (0.56) | L3MBTL1CNR2CNR1BCHEACHE | |
| SCHEMBL6581447 | 0.78 | LMNA (0.55) | L3MBTL1 | |
| SCHEMBL11735500 | 0.78 | L3MBTL1 (0.92) | L3MBTL1CNR2CNR1BCHEATM | |
| SCHEMBL6581952 | 0.77 | KDM4E (0.52) | L3MBTL1ATM | |
| SCHEMBL6579471 | 0.76 | LMNA (0.53) | ATM | |
| SCHEMBL6582307 | 0.76 | KDM4E (0.52) | L3MBTL1CNR2CNR1BCHEATM | |
| SCHEMBL9444758 | 0.74 | SLC22A12 (0.64) | — | |
| SCHEMBL6580094 | 0.73 | KDM4E (0.49) | L3MBTL1CNR2CNR1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1401822-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2004-03-31 | — | — | EP | disclosed |
| US-6599925-B2 | Cardiovascular disorders; anticancer agents | WYETH | 2003-07-29 | — | — | US | disclosed |
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH | 2003-01-23 | — | — | US | disclosed |
| WO-2003000671-A1 | NAPHTHYL BENZOFURAN DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018067-A1 | Substituted naphthyl benzofuran derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | F2R, SERPINE1, SERPINC1 | L3MBTL1 2248/4885CNR2 279/4885CNR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.